From Lab to Market: The Deep Tech Commercialization Path

Deep tech commercialization is not simply a slower version of consumer software commercialization. It is a fundamentally different process with different risk profiles, different capital requirements, different customer relationships, and — crucially — different intellectual property dynamics. Investors and founders who approach deep tech with the mental models formed in software investing tend to make systematic errors in planning, funding, and IP strategy. This piece aims to describe the deep tech commercialization path as it actually works, with specific attention to the IP decisions that shape outcomes at each stage.

The term "deep tech" has been somewhat diluted by overuse, but for our purposes it refers specifically to companies whose core value proposition is rooted in a genuine scientific or engineering advance — not a business model innovation, user experience improvement, or market timing insight. These are companies building novel materials, novel AI systems, quantum devices, advanced biotechnology, new semiconductor architectures, or breakthrough energy technologies. The common thread is that their competitive advantage is fundamentally technical, and protecting that advantage requires a more sophisticated and deliberate approach to intellectual property than is typical in software.

Stage One: Technology Validation (Pre-Company, Years -2 to 0)

Most deep tech companies trace their origins to university research, government laboratory work, or corporate R&D programs. The technology validation stage — often partially or entirely pre-company — is where the foundational inventions are made and, too often, where critical IP decisions are made poorly or not at all.

University-originated deep tech faces a specific IP challenge: the technology has typically been developed using university resources, which means the university technology transfer office (TTO) holds the initial patent rights and the founders must negotiate a license before they can build a company. The quality of these licenses varies enormously across institutions. The best TTOs — MIT, Stanford, Caltech, CMU — have decades of experience structuring spinout licenses that give founders enough room to build commercial companies while preserving appropriate benefit-sharing with the institution. The worst create licenses so encumbered with milestone payments, royalty stacks, and field-of-use restrictions that the resulting company cannot attract outside investment.

For corporate R&D spinouts, the IP challenge is different: the company must negotiate an assignment or exclusive license of technology from the parent corporation, which may have competing commercial interests, contractual restrictions with customers or partners, and institutional inertia that slows the licensing process. The terms of these corporate IP transfers are critically important to evaluate before investing in a spinout.

Regardless of the origin, the pre-company period is when the most consequential patent filing decisions must be made. Inventors who delay filing while they continue their research risk creating prior art through publications, conference presentations, or competing researchers' independent discoveries. The provisional patent application is an invaluable tool here: a well-drafted provisional preserves the priority date of the invention for twelve months while allowing the inventors to continue refining their work before committing to the full patent prosecution process.

Stage Two: Proof of Concept (Months 0-18 of Company Life)

The proof of concept stage is where the company transitions from "we have an interesting scientific result" to "we have a reproducible technical capability that can be the foundation of a commercial product." This is typically the period covered by a seed round, and it is the stage at which NL Patent AI Capital makes most of its investments.

The IP priorities at the proof of concept stage are clear: prosecute the foundational patents aggressively, file continuation applications to expand claim coverage as the technical understanding of the invention deepens, and begin building the trade secret infrastructure that will protect the tacit know-how that cannot be fully captured in patent claims.

Trade secrets deserve more attention than they typically receive at this stage. For AI companies, the most valuable trade secrets are often the training datasets, the specific hyperparameter configurations that achieve best performance, and the informal engineering intuitions that allow the team to iterate rapidly on model improvement. These cannot be patented (training data are not patentable; hyperparameter choices are generally not patentable), but they can be protected through confidentiality agreements, access controls, and employment agreements with appropriate restrictive covenants.

The proof of concept stage is also when the company must make its first serious decision about publication versus patent prosecution. Academic founders are often under intense pressure — from their institutions, from their professional communities, and from their own intellectual instincts — to publish their results. Publication is not inherently incompatible with a strong IP strategy, but it requires careful sequencing: file the patent application first, then publish the paper after the priority date is established. The companies that get this sequencing right preserve their IP options; the companies that publish first may find that their own publications constitute prior art that limits the scope of their subsequent filings.

Stage Three: First Commercial Application (Years 2-4)

The first commercial application stage is where deep tech companies most commonly stumble. Having proven that the technology works in a controlled laboratory setting, they face the far more difficult challenge of demonstrating that it works reliably at the scale and in the conditions required by real commercial customers.

For AI companies, the first commercial application challenge is often about reliability, interpretability, and integration rather than raw performance. A machine learning model that achieves 95% accuracy in a research evaluation may perform at 80% in production, where the input data distribution is noisier, more varied, and less carefully curated than the evaluation dataset. Closing this gap requires substantial engineering investment — in data pipelines, monitoring systems, model retraining infrastructure, and human review processes — that is distinct from the core AI research investment and that generates its own category of patentable innovations.

The first commercial application stage is also when the company's IP strategy must begin to account for competitor responses. Early-stage deep tech companies often operate in relative obscurity during the technology validation and proof of concept stages; their first commercial success brings them to the attention of better-resourced competitors who may attempt to replicate, design around, or invalidate their IP. This is the stage when maintaining a robust freedom-to-operate analysis, monitoring competitor patent filings, and considering inter partes review filing strategies for particularly threatening competitor patents becomes a business-critical activity.

Stage Four: Scale-Up and Platform Building (Years 4-8)

The scale-up stage is where successful deep tech companies begin to realize the long-term value of their early IP investments. As the commercial application matures and the customer base grows, the company has the opportunity to expand its patent portfolio from covering the core innovation to covering the application ecosystem — the integrations, the downstream applications, the improved versions, and the adjacent innovations that emerge from working with real customers at scale.

Platform thinking in IP strategy means building a portfolio that covers not just the current product but the next three generations of products. It means filing patents on improvements to the core technology as they are developed, even when those improvements seem incremental at the time. And it means thinking about licensing — both licensing out to customers and partners who want to use the technology, and licensing in from adjacent patent holders whose IP may be needed for the company's future product roadmap.

The scale-up stage is also typically when a deep tech company becomes attractive to large strategic acquirers. M&A transactions in deep tech are frequently IP-driven: the acquirer is buying the patent portfolio and the technical team, not just the current revenue run rate. Companies that have invested systematically in their IP portfolios from the earliest stage — filing comprehensive patents, prosecuting them effectively through examination, and maintaining clear chain of title — command significantly higher acquisition premiums than companies with equivalent revenue but thinner or messier IP portfolios.

The Capital Efficiency of Early IP Investment

One of the most consistent findings from our investment experience is that deep tech companies that invest heavily in IP at the earliest stages — even when that investment feels expensive relative to the company's current size — generate dramatically better long-term capital efficiency than those who defer IP investment until later stages.

The math is simple. A provisional patent application costs a few thousand dollars at the seed stage. A national phase entry into five key jurisdictions costs approximately $50,000-$100,000 over the first three to four years of prosecution. A comprehensive patent portfolio covering a foundational AI technology in major markets — achieved by a company that started filing aggressively at the seed stage — might ultimately cost $500,000 to $2 million in prosecution expenses over the full development period.

That $2 million investment, if it produces a genuinely broad and defensible patent portfolio in a commercially important AI technology category, can easily generate hundreds of millions of dollars in licensing revenue, M&A premium, or competitive moat value. The companies that defer IP investment because it "seems too expensive" at the seed stage are making a category error: they are treating IP prosecution as a current-period expense rather than as a capital investment with an exceptional expected return.

To explore NL Patent AI Capital's approach to supporting deep tech companies through the commercialization journey, visit our About page or reach out via Contact.